N-heterocyclic inhibitors of TNF-α expression
US7253174B2 · kind B2 · utility
12Cited by
3References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 12, 2006 |
| Grant date | Aug 7, 2007 |
| Priority date | — |
| Expiry date | Jul 12, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I):Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.